Mobile

A randomised phase II double blind placebo controlled trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) with multip...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000113-38

A randomised phase II double blind placebo controlled trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) with multiple brain metastases

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To estimate the effect on neurological progression-free survival at 2 months (n = neurological progression or death) of WBRT, with concomitant Tarceva compared to WBRT alone in patients with advanced NSCLC with multiple brain metastases

Critère d'inclusion

  • Advanced non-small cell lung cancer with multiple brain metastases

Liens